Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb (BMY) stock slips as its anemia drug Reblozyl misses primary goal in a Phase 3 trial for myelofibrosis, ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent pivotal trial failures—still plans to discuss a potential approval filin | ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

(Reuters) -Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.